Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Perhexiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 known ✓ | P23786 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perhexiline SCHEMBL13417497 | 1.00 | CYP2D6 (1.00) | CYP2D6MEN1LMNATP53KMT2A | |
| Perhexiline SCHEMBL15516137 | 1.00 | CYP2D6 (1.00) | CYP2D6MEN1LMNATP53KMT2A | |
| Perhexiline SCHEMBL114894 | 1.00 | CYP2D6 (1.00) | CYP2D6MEN1LMNATP53KMT2A | |
| Perhexiline SCHEMBL4831305 | 0.98 | CYP2D6 (0.96) | CYP2D6MEN1LMNATP53KMT2A | |
| Perhexiline SCHEMBL28885519 | 0.98 | CYP2D6 (0.96) | CYP2D6MEN1LMNATP53KMT2A | |
| Perhexiline SCHEMBL29089418 | 0.98 | CYP2D6 (0.96) | CYP2D6MEN1LMNATP53KMT2A | |
| Perhexiline SCHEMBL16237937 | 0.94 | CYP2D6 (0.89) | CYP2D6MEN1LMNATP53KMT2A | |
| SCHEMBL16237276 | 0.89 | CYP2D6 (0.80) | CYP2D6MEN1LMNATP53KMT2A | |
| Perhexiline SCHEMBL11451421 | 0.89 | LMNA (0.80) | CYP2D6MEN1LMNATP53KMT2A | |
| SCHEMBL16237275 | 0.89 | CYP2D6 (0.80) | CYP2D6MEN1LMNATP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 923 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013182519-A1 | COMBINATION OF LYSOSOMOTROPIC OR AUTOPHAGY MODULATING AGENTS AND A GSK-3 INHIBITOR FOR TREATMENT OF CANCER | UNIVERSITAET BASEL (CH) | 2013-12-12 | — | — | WO | claimed |
| EP-2655619-A1 | AUTOPHAGY INDUCER AND INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NEOPLASMS | Genentech, Inc. (US) | 2013-10-30 | — | — | EP | claimed |
| WO-2012087336-A1 | AUTOPHAGY INDUCER AND INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NEOPLASMS | GENENTECH, INC. (US) | 2012-06-28 | — | — | WO | claimed |
| WO-2012088254-A1 | AUTOPHAGY INDUCER AND INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NEOPLASMS | GENENTECH, INC. (US) | 2012-06-28 | — | — | WO | claimed |
| US-20110071767-A1 | Hepatotoxicity Molecular Models | OCIMUM BIOSOLUNTIONS, INC. (IN) | 2011-03-24 | — | — | US | claimed |
| US-7868036-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-01-11 | — | — | US | claimed |
| WO-2009114729-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL STORAGE DISEASES AND DISORDERS | IRM LLC (BM) | 2009-09-17 | — | — | WO | claimed |
| EP-1717226-B1 | 2,7-SUBSTITUTED 5-AMINO-4-HYDROXY-8-(1H-INDOL-5-YL)-OCTAN AMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | SPEEDEL EXPERIMENTA AG (CH) | 2009-01-21 | — | — | EP | claimed |
| US-20080280895-A1 | 5-Amino-4-Hydroxy-7-(1H-Indolmethyl)-8-Methylnonamide Derivatives as Renin Inhibitors for the Treatment of Hypertension | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | claimed |
| US-20080058320-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-03-06 | — | — | US | claimed |
| WO-2005090305-A1 | 5-AMINO-4-HYDROXY-7-(1H-INDOLMETHYL)-8-METHYLNONAMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | claimed |
| WO-2005090304-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | claimed |
| EP-1507813-A1 | FAT BINDING USING INTER-POLYMER COMPLEX OF GLUCOSAMINE AND POLYACRYLIC ACID | Ranbaxy Laboratories Limited (IN) | 2005-02-23 | — | — | EP | claimed |
| EP-1385501-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | Atherogenics, Inc. (US) | 2004-02-04 | — | — | EP | claimed |
| WO-2003097714-A1 | FAT BINDING USING INTER-POLYMER COMPLEX OF GLUCOSAMINE AND POLYACRYLIC ACID | RANBAXY LABORATORIES LIMITED (IN) | 2003-11-27 | — | — | WO | claimed |
| US-20030162824-A1 | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor | PHARMACIA CORPORATION | 2003-08-28 | — | — | US | claimed |
| US-20030158097-A1 | P-glycoprotein modifier-containing medicinal compositions to be delivered to the large intestine | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2003-08-21 | — | — | US | claimed |
| WO-2002087556-A9 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS INC (US) | 2003-03-20 | — | — | WO | claimed |
| EP-1260233-A1 | P-GLYCOPROTEIN MODIFIER-CONTAINING MEDICINAL COMPOSITIONS TO BE DELIVERED TO THE LARGE INTESTINE | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 2002-11-27 | — | — | EP | claimed |
| WO-2002087556-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS, INC. (US) | 2002-11-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162824-A1 | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor | PTGS1, PTGIS, TNNT2 | CPT2 253/4885CYP2D6 906/4885MEN1 3212/4885 |
| US-20080280895-A1 | 5-Amino-4-Hydroxy-7-(1H-Indolmethyl)-8-Methylnonamide Derivatives as Renin Inhibitors for the Treatment of Hypertension | REN, AGTR1, AGTR2 | CPT2 1944/4885CYP2D6 159/4885MEN1 1485/4885 |
| US-20080058320-A1 | Organic Compounds | REN, AGTR1, ADH1C | CPT2 2824/4885CYP2D6 115/4885MEN1 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.